isatuximab-irfc
| Brand name | Sarclisa Escena |
|---|---|
| Active ingredient | isatuximab-irfc |
| Strength | 1,400MG/10ML (140MG/ML) |
| Dosage form | Injection |
| Route | Subcutaneous |
| Modality | Biologic |
| FDA approval | July 2026 |
| Marketing status | Rx |
Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.